NY-METLIFE
MetLife, Inc. (NYSE: MET) today announced a number of changes to its senior leadership team. All changes are effective on January 1, 2021, unless otherwise noted.
Executive Vice President and President of the Latin America region Oscar Schmidt will retire after a distinguished 26-year career with the company. He will step away from his executive position on December 31, 2020, and will stay on through the end of March 2021 to assist with the leadership transition.
“Over the past two and a half decades, Oscar has helped us grow and develop our Latin America business, building a well-diversified portfolio of businesses across the region,” said MetLife President and CEO Michel Khalaf. “Under his strong leadership, we have grown to become the largest life insurer in Latin America – a distinction achieved organically and through a number of acquisitions.”
Succeeding Schmidt as Regional President, Latin America, will be Eric Clurfain , Executive Vice President and Chairman, President and CEO of MetLife Japan K.K., subject to the necessary approvals. He will report to Khalaf.
“With more than two decades of insurance experience, Eric has a proven track record of building high-performing teams and businesses and a deep commitment to our associates and customers,” Khalaf said. “Over the past two years, his intense focus on business execution and customer centricity has driven culture change in Japan and delivered strong results in support of our Next Horizon strategy. Under his leadership, I am confident LatAm will continue to be a growth engine for MetLife.”
Clurfain’s career path has spanned numerous geographies and strategic leadership responsibilities. Prior to his current role, Clurfain was Regional Head for EMEA with oversight over the region’s 25 markets. Previously, he was Regional Head for Central and Eastern Europe after serving as General Manager of MetLife in Turkey. Earlier in his career with AIG/Alico, Clurfain lived and worked in Latin America.
Succeeding Clurfain as Executive Vice President and Chairman, President and CEO of MetLife Japan K.K. will be Dirk Ostijn , Head of EMEA, subject to the necessary approvals. Ostijn will report to Executive Vice President Kishore Ponnavolu , Regional President, Asia.
“Dirk has successfully led our EMEA region through a challenging operating environment,” Khalaf said. “Under his leadership, the EMEA team built strong momentum with a robust pipeline of new business opportunities, a relentless focus on efficiency, and a diversified model spanning more than 25 markets. I know his exemplary leadership, deep insurance expertise, and passion for the customer will be welcomed and appreciated by our team in Japan.”
With more than 30 years of experience, Ostijn’s career encompasses all aspects of the life insurance industry, including product, finance, operations, customer service and technology. He also spent more than a decade managing insurance brokerage operations, served as a General Manager in Belgium and held regional roles such as chief financial officer and head of strategic initiatives.
Succeeding Ostijn as Head of EMEA will be Nuria Garcia , Senior Vice President and Deputy Head of EMEA. She will report to Khalaf.
“Nuria has a strong focus on business development and partnerships as well as a passion for the customer,” Khalaf said. “She is a highly effective leader who can connect internal and external stakeholders to collaborate across business, function and market. Her leadership played an integral role in the region’s continued strong performance, and I have every confidence that she will continue to build on this track record going forward.”
Garcia has more than 20 years of experience in EMEA spanning distribution, marketing, operations and finance, both with MetLife and GE.
“Taken together, these moves demonstrate not only our commitment to talent development and succession planning, but our deep bench of leaders who are ready to step up immediately and deliver value to our customers and shareholders,” Khalaf said.
About MetLife
MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates ("MetLife"), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management to help its individual and institutional customers navigate their changing world. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com .
Forward-Looking Statements
The forward-looking statements in this disclosure, using words such as “will,” are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife’s future results could differ, and it has no obligation to correct or update any of these statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201015005425/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
